The cross‐over of statistical thinking and practices: A pandemic catalyst

Abstract

Written during the SARS‐CoV‐2 pandemic, and in recognition of Andy Grieve, the polymath, this article looks at an eclectic mix of topics where statistical thinking and practices should transcend typical dividing lines—with a particular focus on the areas of drug development, public health and social science. The case is made for embedding an experimental (or quasi‐experimental) framework within clinical practice for vaccines and treatments following their marketing authorisation. A similar case is made for public health interventions—facilitated by pre‐specification of effect size and by the greater use of data standards. A number of recommendations are made whilst noting that progress is being made in some areas.